Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential FLAMSA followed by T cell-depleted reduced-intensity allogeneic stem cell transplantation in elderly AML or high-risk MDS
NL-OMON39744Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Jul 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fludarabine, amsacrine, cytarabine, alemtuzumab, antithymocyte globulin rabbit and 1 more in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by Leiden University Medical Center. Primary endpoints: Eligibility for donor lymphocyte infusion at 6 months, Grade 3-4 non-hematological toxicity and 3 more. Started Jul 2014; status: recruiting.
02
Drugs
fludarabineamsacrinecytarabinealemtuzumabantithymocyte globulin rabbit
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON39744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39744.